Independent
Tenure on this board
1.8 yrs
Also a director at
Mirum Pharmaceuticals Inc (MIRM)Arcutis Biotherapeutics Inc (ARQT)
Meeting calendar
MBX · Annual meeting · Thursday, June 4, 2026
Mbx Biosciences Inc
2 nominees · 2 ballot items.
Elect two Class II directors (Patrick J. Heron and Edward T. Mathers) to three-year terms and ratify Ernst & Young LLP as MBX’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$3.0B
1Y TSR
+314.9%
Board grade
C
Record date
Apr 10, 2026
Filing
DEF 14A
Meeting concluded · Jun 4, 2026
Follow how the vote landed and what changed on Mbx Biosciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors
ManagementBoard: FORElect two Class II directors (Patrick J. Heron and Edward T. Mathers) to serve three-year terms ending at the 2029 annual meeting.
- 2
Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026
ManagementBoard: FORRatify the Audit Committee’s appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
1.8 yrs
Also a director at
Onkure Therapeutics Inc (OKUR)Trevi Therapeutics Inc (TRVI)Senti Biosciences Holdings Inc (SNTI)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 14.0% | 6,652,013 | $199M |
| 2 | ORBIMED ADVISORS LLCActivist | 7.6% | 3,637,887 | $109M |
| 3 | NEA Management Company, LLC | 7.6% | 3,614,486 | $108M |
| 4 | FMR LLC | 6.0% | 2,844,326 | $85M |
| 5 | Deep Track Capital, LP | 5.8% | 2,757,569 | $82M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 5.6% | 2,664,927 | $80M |
| 7 | NVP Associates, LLC | 4.5% | 2,136,335 | $64M |
| 8 | Polar Capital Holdings Plc | 3.4% | 1,622,186 | $48M |
| 9 | BRAIDWELL LP | 3.1% | 1,492,467 | $45M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,477,592 | $44M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Mbx Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Reference
Frequently asked questions
- When is the Mbx Biosciences Inc 2026 annual meeting?
- Mbx Biosciences Inc (MBX) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.
- What is the record date for the Mbx Biosciences Inc 2026 meeting?
- The record date for the Mbx Biosciences Inc 2026 meeting is Friday, April 10, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Mbx Biosciences Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Mbx Biosciences Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Mbx Biosciences Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Mbx Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.